CAESAREA, Israel and
WALTHAM, Massachusetts,
March 27, 2019 /PRNewswire/ -- Global
digital therapeutics innovator, DarioHealth Corp. (NASDAQ: DRIO),
today announced a joint marketing agreement with Glytec, the market
leader and pioneer of insulin titration solutions for use across
the full continuum of care. The agreement allows DarioHealth's
smart glucose meter (part of the Dario Blood Glucose Monitoring
System) to transmit information to Glytec's Glucommander™
Outpatient software-as-a-medical-device.
Blood glucose data from the Dario Blood Glucose Monitoring
System, automatically sent to the Cloud in real-time, will be
seamlessly imported to Glucommander Outpatient™ and utilized in
conjunction with other clinical data to formulate personalized
insulin dose recommendations. The connected care model supports
virtual insulin titration for outpatients with diabetes.
"The Dario Blood Glucose Monitoring System is growing in
popularity among people with both Type 1 and Type 2 diabetes, and
we are pleased to be able to add DarioHealth to our best-in-class
network of connected device partners," said Bob Leonard, Glytec's President and Chief
Executive Officer. "Glytec doesn't make devices, we make devices
BETTER by adding the missing element, which is insulin
titration. There is little that can be done to achieve and sustain
significant A1c improvements with data alone, but by making that
data actionable and making timely insulin dose adjustments, we see
average reductions in A1c of 2.7% points and higher over 12
months."
The Dario Blood Glucose Monitoring System combines five
essential tools to simplify diabetes management: (1) a sleek,
all-in-one smart glucose meter, (2) a personal diabetes progress
monitor, (3) on-demand data sharing, (4) emergency hypoglycemia
alerts with GPS locator, and (5) a carb counting tool.
"Glytec will benefit from real-time, accurate blood glucose data
to provide insulin titration decision support, and we are convinced
that the Dario Blood Glucose Monitoring System will be a more
complete solution when paired with Glucommander™ Outpatient," said
Erez Raphael, DarioHealth's Chief
Executive Officer. "We believe that people with diabetes need this
synergy to be most successful in managing their diabetes."
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading global Digital
Therapeutics (DTx) company revolutionizing the way people manage
their health across the chronic condition spectrum. By delivering
evidence-based interventions that are driven by data, high-quality
software and coaching, we developed a novel approach that empowers
individuals to adjust their lifestyle in a personalized way. Our
Cross Functional Team operates at the intersection of life
sciences, behavioral science and software technology to deliver
highly engaging therapeutic interventions. Already one of the
highest rated diabetes solutions, its user-centric approach is
loved by tens of thousands of consumers around the globe.
DarioHealth is rapidly moving into new chronic conditions and
geographic markets.
About Glytec
Glytec is the pioneer of personalized digital therapeutics,
enabling best practices for insulin optimization across the
continuum of care. The company's patented and FDA-cleared
software-as-a-medical-device solutions improve the safety and
health of people with diabetes in the hospital and at home. Glytec
combines evidence-based decision support technologies with expert
clinical services to make insulin a more effective medication
option for the millions unable to achieve their treatment goals,
leading to reductions in A1C, hypoglycemia and other complications
as well as avoidable ED visits, hospitalizations, readmissions and
drug waste. The company has offices in Waltham, Massachusetts and Greenville, South Carolina. For more
information, visit www.glytecsystems.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. (the "Company") related thereto
contain or may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed
to be forward-looking statements. Without limiting the generality
of the foregoing, words such as "plan," "project," "potential,"
"seek," "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate," or "continue" are intended to identify
forward-looking statements. For example, when the Company states
that Glytec will benefit from real-time, accurate blood glucose
data to provide insulin titration decision support, its conviction
that the Dario Blood Glucose Monitoring System will be a more
complete solution when paired with Glucommander™ and expresses its
belief that people with diabetes need synergy between blood glucose
data to provide insulin titration decision support to be most
successful in managing their diabetes, it is using
forward-looking statements. Readers are cautioned that certain
important factors may affect the Company's actual results and could
cause such results to differ materially from any forward-looking
statements that may be made in this news release. Factors that may
affect the Company's results include, but are not limited to,
regulatory approvals, product demand, market acceptance, impact of
competitive products and prices, product development,
commercialization or technological difficulties, the success or
failure of negotiations and trade, legal, social and economic
risks, and the risks associated with the adequacy of existing cash
resources. Additional factors that could cause or contribute to
differences between the Company's actual results and
forward-looking statements include, but are not limited to, those
risks discussed in the Company's filings with the U.S. Securities
and Exchange Commission. Readers are cautioned that actual results
(including, without limitation, the timing for and results of the
Company's commercial and regulatory plans for Dario) may differ
significantly from those set forth in the forward-looking
statements. The Company undertakes no obligation to publicly update
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
applicable law.
DarioHealth
Contact
Joao
Mendes-Roter
VP
Marketing
joao@mydario.com
347-767-4220
|
Glytec
Contact
Joy Efron
VP
Marketing
jefron@glytecsystems.com
864-263-4160
|
View original
content:http://www.prnewswire.com/news-releases/dariohealth-partners-with-glytec-on-outpatient-diabetes-management-300819237.html
SOURCE DarioHealth Corp.